Department of Radiation Oncology, School of Medicine, University of Pennsylvania, PA 19104, USA.
Nanomedicine (Lond). 2011 Apr;6(3):475-87. doi: 10.2217/nnm.11.8.
To evaluate the novel nanoparticle reconstituted bacteriochlorin e6 bisoleate low-density lipoprotein (r-Bchl-BOA-LDL) for its efficacy as a photodynamic therapy agent delivery system in xenografts of human hepatoblastoma G2 (HepG2) tumors.
MATERIALS & METHODS: Bchl-BOA was encapsulated in the nanoparticle low-density lipoprotein (LDL), a native particle whose receptor's overexpression is a cancer signature for a number of neoplasms. Evaluation of r-Bchl-BOA-LDL as a potential photosensitizer was performed using a tumor response and foot response assay.
RESULTS & DISCUSSION: When compared with controls, tumor regrowth was significantly delayed at injected murine doses of 2 µmole/kg r-Bchl-BOA-LDL after illumination at fluences of 125, 150 or 175 J/cm(2). Foot response assays showed that although normal tissue toxicity accompanied the higher fluences it was significantly reduced at the lowest fluence tested.
This research demonstrates that r-Bchl-BOA-LDL is an effective photosensitizer and a promising candidate for further investigation.
评估新型纳米细菌叶绿素 e6 双油酸酯低密度脂蛋白（r-Bchl-BOA-LDL）作为光动力治疗药物传递系统在人肝癌细胞系 G2（HepG2）肿瘤异种移植物中的疗效。
Bchl-BOA 被包裹在纳米颗粒低密度脂蛋白（LDL）中，LDL 是一种天然颗粒，其受体的过度表达是许多肿瘤的癌症特征。使用肿瘤反应和足部反应测定法评估 r-Bchl-BOA-LDL 作为潜在光敏剂的效果。
与对照组相比，在 125、150 或 175 J/cm²的照射剂量下，在 2 µmole/kg 的 r-Bchl-BOA-LDL 注射剂量下，肿瘤再生长明显延迟。足部反应试验表明，尽管在较高的照射剂量下伴随有正常组织毒性，但在测试的最低照射剂量下，毒性显著降低。
这项研究表明 r-Bchl-BOA-LDL 是一种有效的光敏剂，是进一步研究的有前途的候选药物。
